Davide AUDISIO was born in 1981 in Cuneo (Italy). After a M.Sc. in pharmaceutical chemistry (Turin, Italy), he moved to France in 2007 to pursue a PhD degree in medicinal chemistry at the University Paris-Sud (Châtenay-Malabry), where he developed new novobiocin derivatives as potential Hsp90 inhibitors under the supervision of D^r. Mouâd Alami and D^r. Samir Messaoudi. In 2010, he joined the group of Prof. Nuno Maulide at the Max-Planck-Institut für Kohlenforschung (Mülheim an der Ruhr, Germany), working on asymmetric catalysis and the development of enantio- and diastereoselective synthesis of substituted cyclobutenes. In 2012, he joined the chemistry department of Eli Lilly & Co. (Windlesham, UK), to work on the development of clinical candidates for neurodegenerative diseases. In 2014, he obtained a permanent position at CEA (Saclay), where he joined the group of D^r. Frédéric Taran, focusing on the chemistry of mesoionic heterocycles and the development of click and release reactions. Since 2016, Davide took the direction of the laboratory of carbon-14 radiolabeling (CEA). His research interests span diverse areas within organic chemistry, including carbon isotope labeling methodologies, the chemistry of helicene and poly-aromatic compounds and the development of new tools for bio-orthogonal chemistry.

In 2017, he obtained the Young Investigator Award in Medicinal Chemistry of the SCT (Société de Chimie Thérapeutique) and an ANR-JCJC grant aiming to explore the use of mesoionics to tackle complex poly-aromatic families. In 2019, he was recipient of an ERC Consolidator Grant devoted to the development of late-stage radiocarbon labeling.